International AIDS Vaccine Initiative
A003 Protocol - A Phase 1, randomized, blinded, dose-escalation study of rAAV1-PG9DP recombinant AAV vector coding for PG9 antibody in healthy male adults
Frances H. Priddy
Table for Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa
MOESM2 of Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes
Correlation between total and antigen-specific IgG responses and development of broadly neutralizing antibody responses.
Specificities mediating neutralization breadth and potency in the top 42 Protocol C neutralizers.
Evolution of broadly neutralizing antibody responses in plasma from Protocol C participants.
Correlation between clinical parameters and development of broadly neutralizing antibody responses.
Supporting figures and tables.
HIV prevalence and multivariate predictors of prevalent HIV infection in Masaka, Kilifi and Nairobi.
Enrollment and HIV incidence among at-risk volunteers enrolled for HIV prevention preparatory studies stratified by CRC and, where appropriate, sex.